Melatonin Inhibits Osteoclastogenesis and Osteolytic Bone Metastasis: Implications for Osteoporosis

doi:10.3390/ijms22179435

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/24226

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24226

题名:	Melatonin Inhibits Osteoclastogenesis and Osteolytic Bone Metastasis: Implications for Osteoporosis
作者:	MacDonald, IJ;Tsai, HC;Chang, AC;Huang, CC;Yang, SF;Tang, CH
关键词:	apoptosis;bone mass protection;bone metastasis;immunomodulation;melatonin;osteoclastogenesis;osteoclasts;osteoporosis
日期:	2021
上传时间:	2022-08-05T10:45:07Z (UTC)
出版者:	MDPI
摘要:	Osteoblasts and osteoclasts are major cellular components in the bone microenvironment and they play a key role in the bone turnover cycle. Many risk factors interfere with this cycle and contribute to bone-wasting diseases that progressively destroy bone and markedly reduce quality of life. Melatonin (N-acetyl-5-methoxy-tryptamine) has demonstrated intriguing therapeutic potential in the bone microenvironment, with reported effects that include the regulation of bone metabolism, acceleration of osteoblastogenesis, inhibition of osteoclastogenesis and the induction of apoptosis in mature osteoclasts, as well as the suppression of osteolytic bone metastasis. This review aims to shed light on molecular and clinical evidence that points to possibilities of melatonin for the treatment of both osteoporosis and osteolytic bone metastasis. It appears that the therapeutic qualities of melatonin supplementation may enable existing antiresorptive osteoporotic drugs to treat osteolytic metastasis.
URI:	http://dx.doi.org/10.3390/ijms22179435 https://www.webofscience.com/wos/woscc/full-record/WOS:000694413300001 https://ir.csmu.edu.tw:8080/handle/310902500/24226
關聯:	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES ,2021 ,v22 ,issue17
显示于类别:	[中山醫學大學研究成果] 其他文獻

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	245	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....